Arch Biopartners, Inc. (ARCH.V)
1.07
-0.09
(-7.76%)
CAD |
TSXV |
Aug 25, 16:00
Arch Biopartners Enterprise Value : 74.76M for Aug. 25, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 25, 2026 | 74.76M |
| August 24, 2026 | 80.86M |
| August 21, 2026 | 78.15M |
| August 20, 2026 | 70.70M |
| August 19, 2026 | 76.79M |
| August 18, 2026 | 80.18M |
| August 17, 2026 | 76.12M |
| August 14, 2026 | 77.47M |
| August 13, 2026 | 80.18M |
| August 12, 2026 | 76.79M |
| August 11, 2026 | 76.12M |
| August 10, 2026 | 81.53M |
| August 07, 2026 | 74.08M |
| August 06, 2026 | 63.93M |
| August 05, 2026 | 65.28M |
| August 04, 2026 | 59.18M |
| July 31, 2026 | 57.15M |
| July 30, 2026 | 59.86M |
| July 29, 2026 | 60.54M |
| July 28, 2026 | 60.54M |
| July 27, 2026 | 59.86M |
| July 24, 2026 | 61.22M |
| July 23, 2026 | 61.89M |
| July 21, 2026 | 60.54M |
| July 20, 2026 | 59.86M |
| Date | Value |
|---|---|
| July 17, 2026 | 59.18M |
| July 16, 2026 | 59.86M |
| July 15, 2026 | 59.86M |
| July 14, 2026 | 59.18M |
| July 13, 2026 | 58.51M |
| July 10, 2026 | 60.54M |
| July 09, 2026 | 57.83M |
| July 08, 2026 | 57.83M |
| July 07, 2026 | 55.80M |
| July 06, 2026 | 55.80M |
| July 03, 2026 | 64.60M |
| July 02, 2026 | 60.54M |
| June 30, 2026 | 55.80M |
| June 29, 2026 | 57.15M |
| June 26, 2026 | 66.63M |
| June 25, 2026 | 62.57M |
| June 24, 2026 | 73.41M |
| June 23, 2026 | 69.34M |
| June 22, 2026 | 59.18M |
| June 19, 2026 | 47.67M |
| June 18, 2026 | 44.96M |
| June 17, 2026 | 36.83M |
| June 16, 2026 | 35.48M |
| June 15, 2026 | 35.48M |
| June 12, 2026 | 36.83M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Innovotech, Inc. | 4.192M |
| Kane Biotech, Inc. | 6.069M |
| Quest PharmaTech, Inc. | 4.368M |
| BriaCell Therapeutics Corp. | 5.345M |
| Vaxil Bio Ltd. | 0.1104M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -0.521M |
| Total Expenses (Quarterly) | 0.521M |
| EPS Diluted (Quarterly) | -0.0078 |
| Earnings Yield | -3.66% |
| Normalized Earnings Yield | -3.654 |